Бронхиальная астма и сердечно-сосудистые заболевания

2. Мельникова Т.А. Показатели эффективности мер демографической политики Российской Федерации. Гос. служба. 2015; 1 (93): 84–7. / Mel'nikova T.A. Pokazateli effektivnosti mer demograficheskoj politiki Rossijskoj Federacii. Gos. sluzhba. 2015; 1 (93): 84–7. [in Russian]
3. Fortin M, Bravo G, Hudon C et al. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med 2005; 3: 8–223.
4. Fortin M, Lapointe L, Hudon C et al. Multimorbidity and quality of life in primary care: a systematic review. Health Qual Life Outcomes 2004; 2 (20): 51.
5. Guiding Principles for the Care of Older Adults with Multimorbidity: An Approach for Clinicians. J Am Geriatrics Soc 2012; 60: 1–25.
6. Ширинский В.С., Ширинский И.В. Коморбидные заболевания – актуальная проблема клинической медицины. Сибирский мед. журн. 2014; 1 (29): 7–12. / Shirinskij V.S., Shirinskij I.V. Komorbidnye zabolevaniya – aktual'naya problema klinicheskoj mediciny. Sibirskij med. zhurn. 2014; 1 (29): 7–12. [in Russian]
7. Верткин А.Л., Скотников А.С., Губжокова О.М. Коморбидность при хронической обструктивной болезни легких: роль хронического системного воспаления и клинико-фармакологические ниши рофлумиласта. Лечащий врач. 2013; 9: 20–4. / Vertkin A.L., Skotnikov A.S., Gubzhokova O.M. Komorbidnost' pri hronicheskoj obstruktivnoj bolezni legkih: rol' hronicheskogo sistemnogo vospaleniya i kliniko-farmakologicheskie nishi roflumilasta. Lechashchij vrach. 2013; 9: 20–4. [in Russian]
8. Cazzola M, Calzetta L, Bettoncelli G et al. Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. Respir Med 2012; 106: 249–56.
9. Задионченко В.С. Клинико-функциональные особенности артериальной гипертонии у больных хроническими обструктивными болезнями легких. Рус. мед. журн. 2003; 9 (11): 35–9. / Zadionchenko V.S. Kliniko-funkcional'nye osobennosti arterial'noj gipertonii u bol'nyh hronicheskimi obstruktivnymi boleznyami legkih. Rus. med. zhurn. 2003; 9 (11): 35–9. [in Russian]
10. Урясьев О.М. Бронхиальная астма и коморбидная кардиальная патология: частота и клинико-функциональные особенности. Земский врач. 2012; 3 (20): 22–7. / Uryas'ev O.M. Bronhial'naya astma i komorbidnaya kardial'naya patologiya: chastota i kliniko-funkcional'nye osobennosti. Zemskij vrach. 2012; 3 (20): 22–7. [in Russian]
11. Урясьев О.М. Бронхиальная астма и заболевания сердечно-сосудистой системы. Земский врач. 2015; 4: 5–14. / Uryas'ev O.M. Bronhial'naya astma i zabolevaniya serdechno-sosudistoj sistemy. Zemskij vrach. 2015; 4: 5–14. [in Russian]
12. Кушелевский Б.Г., Ренева Т.Г. Сочетание бронхиальной астмы и гипертонической болезни как пример конкурирующих заболеваний. Терапевт. архив. 1961; 6 (36): 62–7. / Kushelevskij B.G., Reneva T.G. Sochetanie bronhial'noj astmy i gipertonicheskoj bolezni kak primer konkuriruyushchih zabolevanij. Terapevt. аrhiv. 1961; 6 (36): 62–7. [in Russian]
13. Мухарлямов Н.М., Саттбеков Ж.С., Сучков В.В. Системная артериальная гипертензия у больных хроническими неспецифическими заболеваниями легких. Кардиология. 1974; 12 (34): 55–61. / Muharlyamov N.M., Sattbekov Zh.S., Suchkov V.V. Sistemnaya arterial'naya gipertenziya u bol'nyh hronicheskimi nespecificheskimi zabolevaniyami legkih. Kardiologiya. 1974; 12 (34): 55–61. [in Russian]
14. Каримов Д.С., Алимов А.Т. К вопросу системной артериальной гипертензии при бронхиальной астме. Сб. науч. тр. Ташкент, 1982; с. 39–42. / Karimov D.S., Alimov A.T. K voprosu sistemnoj arterial'noj gipertenzii pri bronhial'noj astme. Sb. nauch. tr. Tashkent, 1982; s. 39–42. [in Russian]
15. Бобров В.А. Состояние миокарда, гуморальные субстанции у больных с бронхиальной астмой и артериальной гипертензией. Клин. медицина. 1989; 11: 31–5. / Bobrov V.A. Sostoyanie miokarda, gumoral'nye substancii u bol'nyh s bronhial'noj astmoj i arterial'noj gipertenziej. Klin. medicina. 1989; 11: 31–5. [in Russian]
16. Dart RA, Gollub S, Lazar J. Treatment of Systemic Hypertension in Patients With Pulmonary Disease. Chest 2003; 123: 222–43.
17. Жданов В.Ф., Амосов В.И., Синицына Т.М. и др. Особенности легочной микроциркуляции и функции внешнего дыхания у больных бронхиальной астмой с системной артериальной гипертензией. Терапевтич. архив. 199; 10 (63): 144–6. / Zhdanov V.F., Amosov V.I., Sinicyna T.M. i dr. Osobennosti legochnoj mikrocirkulyacii i funkcii vneshnego dyhaniya u bol'nyh bronhial'noj astmoj s sistemnoj arterial'noj gipertenziej. Terapevtich. аrhiv. 199; 10 (63): 144–6. [in Russian]
18. Ушаков В.Ф. Исследование связи маркеров воспаления с уровнем артериального давления у больных бронхиальной астмой с пульмогенной артериальной гипертензией. Мед. наука и образование Урала. 2010; 4 (11): 87–9. / Ushakov V.F. Issledovanie svyazi markerov vospaleniya s urovnem arterial'nogo davleniya u bol'nyh bronhial'noj astmoj s pul'mogennoj arterial'noj gipertenziej. Med. nauka i obrazovanie Urala. 2010; 4 (11): 87–9. [in Russian]
19. Баранов В.С. Гены предрасположенности, или Болезни, которые нас выбирают. Наука в России. 2003; 1: 27–31. / Baranov V.S. Geny predraspolozhennosti, ili Bolezni, kotorye nas vybirayut. Nauka v Rossii. 2003; 1: 27–31. [in Russian]
20. Урясьев О.М., Шаханов А.В. Роль полиморфизма синтаз оксида азота в формировании коморбидной патологии – бронхиальной астмы и гипертонической болезни. Казанский мед. журн. 2017; 2 (98): 226–32. / Uryas'ev O.M., Shahanov A.V. Rol' polimorfizma sintaz oksida azota v formirovanii komorbidnoj patologii – bronhial'noj astmy i gipertonicheskoj bolezni. Kazanskij med. zhurn. 2017; 2 (98): 226–32. [in Russian]
21. Ушаков В.Ф., Кушникова И.П., Рыбалка О.О. Клиническое течение бронхиальной астмы с сопутствующей артериальной гипертензией. Вестник СурГУ. Медицина. 2013; 1 (15): 37–41. / Ushakov V.F., Kushnikova I.P., Rybalka O.O. Klinicheskoe techenie bronhial'noj astmy s soputstvuyushchej arterial'noj gipertenziej. Vestnik SurGU. Medicina. 2013; 1 (15): 37–41. [in Russian]
22. Гармазина М.В., Будневский А.В. Бронхиальная астма и гипертоническая болезнь: особенности клинико-психологического статуса и реабилитации пациентов с сочетанной патологией. Научно-мед. вестн. центрального Черноземья. 2008; 32: 63–9. / Garmazina M.V., Budnevskij A.V. Bronhial'naya astma i gipertonicheskaya bolezn': osobennosti kliniko-psihologicheskogo statusa i reabilitacii pacientov s sochetannoj patologiej. Nauchno-med. vestn. central'nogo Chernozem'ya. 2008; 32: 63–9. [in Russian]
23. Marshall RP, Gohlke P, Chambers RC. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004; 286: 156–64.
24. Боровков Н.Н., Добротина И.С., Бердникова Л.В. Особенности артериального давления по данным суточного мониторирования у больных артериальной гипертензией на фоне обострения бронхиальной астмы. Мед. альманах. 2012; 1: 152–83. / Borovkov N.N., Dobrotina I.S., Berdnikova L.V. Osobennosti arterial'nogo davleniya po dannym sutochnogo monitorirovaniya u bol'nyh arterial'noj gipertenziej na fone obostreniya bronhial'noj astmy. Med. al'manah. 2012; 1: 152–83. [in Russian]
25. Доля Е.М. Вопросы патогенеза и лечения артериальной гипертензии у больных бронхиальной астмой. Крымский терапевтич. журн. 2014; 1: 45–50. / Dolya E.M. Voprosy patogeneza i lecheniya arterial'noj gipertenzii u bol'nyh bronhial'noj astmoj. Krymskij terapevtich. zhurn. 2014; 1: 45–50. [in Russian]
26. Кароли Н.А., Рощина А.А., Ребров А.П. Роль пролонгированного антагониста кальция (амлодипина малеат) в лечении артериальной гипертензии у больных бронхиальной астмой. Клиницист. 2011; 5 (1): 54–9. / Karoli N.A., Roshchina A.A., Rebrov A.P. Rol' prolongirovannogo antagonista kal'ciya (amlodipina maleat) v lechenii arterial'noj gipertenzii u bol'nyh bronhial'noj astmoj. Klinicist. 2011; 5 (1): 54–9. [in Russian]
27. Кочкина М.С., Затейщиков Д.А., Сидоренко Б.А. Измерение жесткости артерий и ее клиническое значение. Кардиология. 2005; 1: 63–71. / Kochkina M.S., Zatejshchikov D.A., Sidorenko B.A. Izmerenie zhestkosti arterij i ee klinicheskoe znachenie. Kardiologiya. 2005; 1: 63–71. [in Russian]
28. Белялов Ф.И. Лечение болезней в условиях коморбидности. М.: ГЭОТАР-Медиа, 2016; с. 544. / Belyalov F.I. Lechenie boleznej v usloviyah komorbidnosti. M.: GEOTAR-Media, 2016; s. 544. [in Russian]
29. Саковец Т.Г., Богданов Э.И. Гипокалиемические миоплегии. Казанский мед. журн. 2013; 6 (94): 933–8. / Sakovec T.G., Bogdanov E.I. Gipokaliemicheskie mioplegii. Kazanskij med. zhurn. 2013; 6 (94): 933–8. [in Russian]
30. Kim J, Purushottam B, Chae YK et al. Relation Between Common Allergic Symptoms and Coronary Heart Disease Among NHANES III Participants. Am J Cardiol 2010; 7 (106): 984–7.
31. Iribarren C, Tolstykh IV, Miller MK et al. Adult Asthma and Risk of Coronary Heart Disease, Cerebrovascular Disease, and Heart Failure: A Prospective Study of 2 Matched Cohorts. Am J Epidemiol 2012; 11 (176): 1014–24.
32. Lee HM, Truong ST, Wong ND. Association of adult-onset asthma with specific cardiovascular conditions. Respir Med 2012; 106: 948–53.
33. Onufrak SJ, Abramson JL, Austin HD et al. Relation of Adult-Onset Asthma to Coronary Heart Disease and Stroke. Am J Cardiol 2008; 101: 1247–52.
34. Appleton SL, Ruffin RE, Wilson DH et al. Asthma is associated with cardiovascular disease in a representative population sample. Obesity Res Clin Practice 2008; 2: 91–9.
35. Miranda C, Busacker A, Balzar S et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113: 8–101.
36. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8–11.
37. Hsu JY, King SL, Kuo BI et al. Age of onset and the characteristics of asthma. Respirology 2004; 9: 72–369.
38. Vrieze A, Postma DS, Kerstjens HA. Perimenstrual asthma: a syndrome without known cause or cure. J Allergy Clin Immunol 2003; 112: 271–82.
39. Petri M. Long-term outcomes in lupus. Am J Manag Care 2001; 7: 480–5.
40. Miller AP, Feng W, Xing D et al. Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries. Circulation 2004; 110: 1664–9.
41. Schanen JG, Iribarren C, Shahar E et al. Asthma and incident cardiovascular disease: the Atherosclerosis Risk in Communities Study. Thorax 2005; 60: 633–8.
42. Поздняков Ю.М. и др. Коронарный больной и коморбидные состояния. Практическое руководство. М., 2012; с. 180. / Pozdnyakov Yu.M. i dr. Koronarnyj bol'noj i komorbidnye sostoyaniya. Prakticheskoe rukovodstvo. M., 2012; s. 180. [in Russian]
43. Appleton SL, Ruffin RE, Wilson DH. Cardiovascular disease risk associated with asthma and respiratory morbidity might be mediated by short-acting b2-agonists. J Allergy Clin Immunol 2009; 123: 30–124.
44. Nelson HS, Weiss ST, Bleecker ER et al. The Salmeterol Multicenter Asthma Research Trial. A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 15 (129): 15–26.
45. Rosero SZ, Zareba W, Moss AJ et al. Asthma and the risk of cardiac events in the long QT syndrome. Am J Cardiol 1999; 12 (84): 1406–11.
46. Fox K, Ford I, Steg PG et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009; 30: 2337–45.
47. Fox K, Ford I, Steg PG et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371: 1091–9.
48. Демко И.В., Гордеева Н.В., Петрова М.М., Артюхов И.П. Клиника и лечение бронхиальной астмы, сочетающейся с патологией сердечно-сосудистой системы. Бюллетень сибирской медицины. 2007; 2: 90–7. / Demko I.V., Gordeeva N.V., Petrova M.M., Artyuhov I.P. Klinika i lechenie bronhial'noj astmy, sochetayushchejsya s patologiej serdechno-sosudistoj sistemy. Byulleten' sibirskoj mediciny. 2007; 2: 90–7. [in Russian]
49. Tse SM, Li L, Butler MG et al. Statin Exposure Is Associated with Decreased Asthma-related Emergenscy Department Visits and Oral Corticosteroid Use. Am J Respir Crit Care Med 201; 9 (188): 1076–82.
50. Yuan C, Zhou L, Cheng J et al. Statin as potential therapeutic drug for asthma? Respir Res 2012; 13: 108.
51. Warnier MJ, Rutten FH, Kors JA et al. Cardiac arrhythmias in adult patients with asthma. J Asthma 2012; 9 (49): 942–6.
52. Garrard CS, Seidler A, McKibben A et al. Spectral analysis of heart rate variability in bronchial asthma. Clin Autonomic Res 1992; 2 (2): 105–11.
53. Пластинина С.C. Нарушения ритма сердца у больных бронхиальной астмой, пути профилактики и способы их коррекции. Дис. … канд. мед. наук. Н. Новгород, 2009. / Plastinina S.C. Narusheniya ritma serdca u bol'nyh bronhial'noj astmoj, puti profilaktiki i sposoby ih korrekcii. Dis. … kand. med. nauk. N. Novgorod, 2009. [in Russian]
54. Bikkina M, Larson MG, Levy D. Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study. Ann Intern Med 1992; 12 (117): 6–990.
55. Saccareccia F. Heart rate as predictor of mortality: the MATISS project. Am J Public Health 2001; 91: 1258–63.
56. Warnier MJ, Rutten FH, de Boer A. Resting heart rate is a risk factor for mortality in chronic obstructive pulmonary disease, but not for exacerbations or pneumonia. PLoS One 2014; 8 (9): 105–52.
57. Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological consideration. J Hum Hypertens 1997; 11 (1): 19–27.
58. Sa Cunha R, Pannier B, Benetos A et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens 1997; 15: 1423–30.
59. Osuorji I, Williams C, Hessney J et al. Acute stress cardiomyopathy following treatment of status asthmaticus. South Med J 2009; 3 (102): 301–3.
60. Helfant RH. Hypokalemia and arrhythmias. Am J Med 1986; 4 (80): 13–22.
61. Марченко В.Н., Трофимов В.И., Александрин В.А. и др. Нейровегетативная регуляция кардиореспираторной функциональной системы у больных бронхиальной астмой. Вестн. совр. клин. мед. 2010; 3: 26–9. / Marchenko V.N., Trofimov V.I., Aleksandrin V.A. i dr. Nejrovegetativnaya regulyaciya kardiorespiratornoj funkcional'noj sistemy u bol'nyh bronhial'noj astmoj. Vestn. sovr. klin. med. 2010; 3: 26–9. [in Russian]
62. Bouvy ML, Heerdink ER, de Bruin ML et al. Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. Arch Intern Med 2000; 16 (160): 2477–80.
63. Rosero SZ, Zareba W, Moss AJ et al. Asthma and the risk of cardiac events in the long QT syndrome. Am J Cardiol 1999; 12 (84): 1406–11.
64. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137: 715–25.
65. Rich J, Thenappan T, Murphy D, O’Callaghan DS. From endothelial progenitor cells to vascular remodelling and more: 6 months in pulmonary hypertension. Int J Clin Pract 2007; 61 (158): 26–36.
66. Демко И.В., Собко Е.А., Кропошина А.Ю. и др. Особенности ремоделирования правых и левых отделов сердца у больных бронхиальной астмой. Сибирское мед. обозрение. 2016; 3 (99): 48–55. / Demko I.V., Sobko E.A., Kroposhina A.Yu. i dr. Osobennosti remodelirovaniya pravyh i levyh otdelov serdca u bol'nyh bronhial'noj astmoj. Sibirskoe med. obozrenie. 2016; 3 (99): 48–55. [in Russian]
67. Гаглошвили Я.К. Клинико-патогенетические особенности формирования легочной гипертензии и сердечно-сосудистых осложнений у больных с бронхиальной астмой. Дис. … канд. мед. наук. М., 2009; с. 126. / Gagloshvili Ya.K. Kliniko-patogeneticheskie osobennosti formirovaniya legochnoj gipertenzii i serdechno-sosudistyh oslozhnenij u bol'nyh s bronhial'noj astmoj. Dis. … kand. med. nauk. M., 2009; s. 126. [in Russian]
68. Granger CB, McMurray JJV, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6.
69. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–200.

________________________________________________

1. Prasolov V.I., Tokarev V.V. Prodolzhitel'nost' zhizni kak kriterij social'noj politiki. Trud i social'nye otnosheniya 2017; 2: 86–103. [in Russian]
2. Mel'nikova T.A. Pokazateli effektivnosti mer demograficheskoj politiki Rossijskoj Federacii. Gos. sluzhba. 2015; 1 (93): 84–7. [in Russian]
3. Fortin M, Bravo G, Hudon C et al. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med 2005; 3: 8–223.
4. Fortin M, Lapointe L, Hudon C et al. Multimorbidity and quality of life in primary care: a systematic review. Health Qual Life Outcomes 2004; 2 (20): 51.
5. Guiding Principles for the Care of Older Adults with Multimorbidity: An Approach for Clinicians. J Am Geriatrics Soc 2012; 60: 1–25.
6. Shirinskij V.S., Shirinskij I.V. Komorbidnye zabolevaniya – aktual'naya problema klinicheskoj mediciny. Sibirskij med. zhurn. 2014; 1 (29): 7–12. [in Russian]
7. Vertkin A.L., Skotnikov A.S., Gubzhokova O.M. Komorbidnost' pri hronicheskoj obstruktivnoj bolezni legkih: rol' hronicheskogo sistemnogo vospaleniya i kliniko-farmakologicheskie nishi roflumilasta. Lechashchij vrach. 2013; 9: 20–4. [in Russian]
8. Cazzola M, Calzetta L, Bettoncelli G et al. Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. Respir Med 2012; 106: 249–56.
9. Zadionchenko V.S. Kliniko-funkcional'nye osobennosti arterial'noj gipertonii u bol'nyh hronicheskimi obstruktivnymi boleznyami legkih. Rus. med. zhurn. 2003; 9 (11): 35–9. [in Russian]
10. Uryas'ev O.M. Bronhial'naya astma i komorbidnaya kardial'naya patologiya: chastota i kliniko-funkcional'nye osobennosti. Zemskij vrach. 2012; 3 (20): 22–7. [in Russian]
11. Uryas'ev O.M. Bronhial'naya astma i zabolevaniya serdechno-sosudistoj sistemy. Zemskij vrach. 2015; 4: 5–14. [in Russian]
12. Kushelevskij B.G., Reneva T.G. Sochetanie bronhial'noj astmy i gipertonicheskoj bolezni kak primer konkuriruyushchih zabolevanij. Terapevt. аrhiv. 1961; 6 (36): 62–7. [in Russian]
13. Muharlyamov N.M., Sattbekov Zh.S., Suchkov V.V. Sistemnaya arterial'naya gipertenziya u bol'nyh hronicheskimi nespecificheskimi zabolevaniyami legkih. Kardiologiya. 1974; 12 (34): 55–61. [in Russian]
14. Karimov D.S., Alimov A.T. K voprosu sistemnoj arterial'noj gipertenzii pri bronhial'noj astme. Sb. nauch. tr. Tashkent, 1982; s. 39–42. [in Russian]
15. Bobrov V.A. Sostoyanie miokarda, gumoral'nye substancii u bol'nyh s bronhial'noj astmoj i arterial'noj gipertenziej. Klin. medicina. 1989; 11: 31–5. [in Russian]
16. Dart RA, Gollub S, Lazar J. Treatment of Systemic Hypertension in Patients With Pulmonary Disease. Chest 2003; 123: 222–43.
17. Zhdanov V.F., Amosov V.I., Sinicyna T.M. i dr. Osobennosti legochnoj mikrocirkulyacii i funkcii vneshnego dyhaniya u bol'nyh bronhial'noj astmoj s sistemnoj arterial'noj gipertenziej. Terapevtich. аrhiv. 199; 10 (63): 144–6. [in Russian]
18. Ushakov V.F. Issledovanie svyazi markerov vospaleniya s urovnem arterial'nogo davleniya u bol'nyh bronhial'noj astmoj s pul'mogennoj arterial'noj gipertenziej. Med. nauka i obrazovanie Urala. 2010; 4 (11): 87–9. [in Russian]
19. Baranov V.S. Geny predraspolozhennosti, ili Bolezni, kotorye nas vybirayut. Nauka v Rossii. 2003; 1: 27–31. [in Russian]
20. Uryas'ev O.M., Shahanov A.V. Rol' polimorfizma sintaz oksida azota v formirovanii komorbidnoj patologii – bronhial'noj astmy i gipertonicheskoj bolezni. Kazanskij med. zhurn. 2017; 2 (98): 226–32. [in Russian]
21. Ushakov V.F., Kushnikova I.P., Rybalka O.O. Klinicheskoe techenie bronhial'noj astmy s soputstvuyushchej arterial'noj gipertenziej. Vestnik SurGU. Medicina. 2013; 1 (15): 37–41. [in Russian]
22. Garmazina M.V., Budnevskij A.V. Bronhial'naya astma i gipertonicheskaya bolezn': osobennosti kliniko-psihologicheskogo statusa i reabilitacii pacientov s sochetannoj patologiej. Nauchno-med. vestn. central'nogo Chernozem'ya. 2008; 32: 63–9. [in Russian]
23. Marshall RP, Gohlke P, Chambers RC. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004; 286: 156–64.
24. Borovkov N.N., Dobrotina I.S., Berdnikova L.V. Osobennosti arterial'nogo davleniya po dannym sutochnogo monitorirovaniya u bol'nyh arterial'noj gipertenziej na fone obostreniya bronhial'noj astmy. Med. al'manah. 2012; 1: 152–83. [in Russian]
25. Dolya E.M. Voprosy patogeneza i lecheniya arterial'noj gipertenzii u bol'nyh bronhial'noj astmoj. Krymskij terapevtich. zhurn. 2014; 1: 45–50. [in Russian]
26. Karoli N.A., Roshchina A.A., Rebrov A.P. Rol' prolongirovannogo antagonista kal'ciya (amlodipina maleat) v lechenii arterial'noj gipertenzii u bol'nyh bronhial'noj astmoj. Klinicist. 2011; 5 (1): 54–9. [in Russian]
27. Kochkina M.S., Zatejshchikov D.A., Sidorenko B.A. Izmerenie zhestkosti arterij i ee klinicheskoe znachenie. Kardiologiya. 2005; 1: 63–71. [in Russian]
28. Belyalov F.I. Lechenie boleznej v usloviyah komorbidnosti. M.: GEOTAR-Media, 2016; s. 544. [in Russian]
29. Sakovec T.G., Bogdanov E.I. Gipokaliemicheskie mioplegii. Kazanskij med. zhurn. 2013; 6 (94): 933–8. [in Russian]
30. Kim J, Purushottam B, Chae YK et al. Relation Between Common Allergic Symptoms and Coronary Heart Disease Among NHANES III Participants. Am J Cardiol 2010; 7 (106): 984–7.
31. Iribarren C, Tolstykh IV, Miller MK et al. Adult Asthma and Risk of Coronary Heart Disease, Cerebrovascular Disease, and Heart Failure: A Prospective Study of 2 Matched Cohorts. Am J Epidemiol 2012; 11 (176): 1014–24.
32. Lee HM, Truong ST, Wong ND. Association of adult-onset asthma with specific cardiovascular conditions. Respir Med 2012; 106: 948–53.
33. Onufrak SJ, Abramson JL, Austin HD et al. Relation of Adult-Onset Asthma to Coronary Heart Disease and Stroke. Am J Cardiol 2008; 101: 1247–52.
34. Appleton SL, Ruffin RE, Wilson DH et al. Asthma is associated with cardiovascular disease in a representative population sample. Obesity Res Clin Practice 2008; 2: 91–9.
35. Miranda C, Busacker A, Balzar S et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113: 8–101.
36. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8–11.
37. Hsu JY, King SL, Kuo BI et al. Age of onset and the characteristics of asthma. Respirology 2004; 9: 72–369.
38. Vrieze A, Postma DS, Kerstjens HA. Perimenstrual asthma: a syndrome without known cause or cure. J Allergy Clin Immunol 2003; 112: 271–82.
39. Petri M. Long-term outcomes in lupus. Am J Manag Care 2001; 7: 480–5.
40. Miller AP, Feng W, Xing D et al. Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries. Circulation 2004; 110: 1664–9.
41. Schanen JG, Iribarren C, Shahar E et al. Asthma and incident cardiovascular disease: the Atherosclerosis Risk in Communities Study. Thorax 2005; 60: 633–8.
42. Pozdnyakov Yu.M. i dr. Koronarnyj bol'noj i komorbidnye sostoyaniya. Prakticheskoe rukovodstvo. M., 2012; s. 180. [in Russian]
43. Appleton SL, Ruffin RE, Wilson DH. Cardiovascular disease risk associated with asthma and respiratory morbidity might be mediated by short-acting b2-agonists. J Allergy Clin Immunol 2009; 123: 30–124.
44. Nelson HS, Weiss ST, Bleecker ER et al. The Salmeterol Multicenter Asthma Research Trial. A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 15 (129): 15–26.
45. Rosero SZ, Zareba W, Moss AJ et al. Asthma and the risk of cardiac events in the long QT syndrome. Am J Cardiol 1999; 12 (84): 1406–11.
46. Fox K, Ford I, Steg PG et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009; 30: 2337–45.
47. Fox K, Ford I, Steg PG et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371: 1091–9.
48. Demko I.V., Gordeeva N.V., Petrova M.M., Artyuhov I.P. Klinika i lechenie bronhial'noj astmy, sochetayushchejsya s patologiej serdechno-sosudistoj sistemy. Byulleten' sibirskoj mediciny. 2007; 2: 90–7. [in Russian]
49. Tse SM, Li L, Butler MG et al. Statin Exposure Is Associated with Decreased Asthma-related Emergenscy Department Visits and Oral Corticosteroid Use. Am J Respir Crit Care Med 201; 9 (188): 1076–82.
50. Yuan C, Zhou L, Cheng J et al. Statin as potential therapeutic drug for asthma? Respir Res 2012; 13: 108.
51. Warnier MJ, Rutten FH, Kors JA et al. Cardiac arrhythmias in adult patients with asthma. J Asthma 2012; 9 (49): 942–6.
52. Garrard CS, Seidler A, McKibben A et al. Spectral analysis of heart rate variability in bronchial asthma. Clin Autonomic Res 1992; 2 (2): 105–11.
53. Plastinina S.C. Narusheniya ritma serdca u bol'nyh bronhial'noj astmoj, puti profilaktiki i sposoby ih korrekcii. Dis. … kand. med. nauk. N. Novgorod, 2009. [in Russian]
54. Bikkina M, Larson MG, Levy D. Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study. Ann Intern Med 1992; 12 (117): 6–990.
55. Saccareccia F. Heart rate as predictor of mortality: the MATISS project. Am J Public Health 2001; 91: 1258–63.
56. Warnier MJ, Rutten FH, de Boer A. Resting heart rate is a risk factor for mortality in chronic obstructive pulmonary disease, but not for exacerbations or pneumonia. PLoS One 2014; 8 (9): 105–52.
57. Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological consideration. J Hum Hypertens 1997; 11 (1): 19–27.
58. Sa Cunha R, Pannier B, Benetos A et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens 1997; 15: 1423–30.
59. Osuorji I, Williams C, Hessney J et al. Acute stress cardiomyopathy following treatment of status asthmaticus. South Med J 2009; 3 (102): 301–3.
60. Helfant RH. Hypokalemia and arrhythmias. Am J Med 1986; 4 (80): 13–22.
61. Marchenko V.N., Trofimov V.I., Aleksandrin V.A. i dr. Nejrovegetativnaya regulyaciya kardiorespiratornoj funkcional'noj sistemy u bol'nyh bronhial'noj astmoj. Vestn. sovr. klin. med. 2010; 3: 26–9. [in Russian]
62. Bouvy ML, Heerdink ER, de Bruin ML et al. Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. Arch Intern Med 2000; 16 (160): 2477–80.
63. Rosero SZ, Zareba W, Moss AJ et al. Asthma and the risk of cardiac events in the long QT syndrome. Am J Cardiol 1999; 12 (84): 1406–11.
64. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137: 715–25.
65. Rich J, Thenappan T, Murphy D, O’Callaghan DS. From endothelial progenitor cells to vascular remodelling and more: 6 months in pulmonary hypertension. Int J Clin Pract 2007; 61 (158): 26–36.
66. Demko I.V., Sobko E.A., Kroposhina A.Yu. i dr. Osobennosti remodelirovaniya pravyh i levyh otdelov serdca u bol'nyh bronhial'noj astmoj. Sibirskoe med. obozrenie. 2016; 3 (99): 48–55. [in Russian]
67. Gagloshvili Ya.K. Kliniko-patogeneticheskie osobennosti formirovaniya legochnoj gipertenzii i serdechno-sosudistyh oslozhnenij u bol'nyh s bronhial'noj astmoj. Dis. … kand. med. nauk. M., 2009; s. 126. [in Russian]
68. Granger CB, McMurray JJV, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6.
69. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–200.

О.Д.Остроумова*1,2, И.В.Голобородова1, Н.Ю.Воеводина3, В.М.Фомина1, А.А.Серегин3 1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119021, Россия, Москва,  ул. Россолимо, д. 11;
3 ГБУЗ «Городская клиническая больница им. Е.О.Мухина» Департамента здравоохранения г. Москвы. 111399, Россия, Москва, Федеративный пр-т, д. 17
*ostroumova.olga@mail.ru

________________________________________________

1 A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119021, Russian Federation, Moscow, ul. Rossolimo, d. 11;
3 E.O.Mukhin City Clinical Hospital of the Department of Health of Moscow. 111399, Russian Federation, Moscow, Federativnyi pr-t, d. 17
*ostroumova.olga@mail.ru